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1. Introduction 
International guidelines have been developed for the use of medications in the treatment of 
substance use disorders (WHO, 2008; WHO, 2009). Medications used in the detoxification 
from drug abuse and dependence provide symptomatic relief of drug and alcohol 
withdrawal. For long term treatment or medical maintenance treatment, medications 
eliminate the physiological effects of drug use by blocking drug-receptor binding in the 
brain and are an important part of the recovery process. The use of medication assistant 
treatment (MAT) is part of a comprehensive treatment plan for drug and alcohol 
dependence that addresses the medical, social, and psychological needs of the patient 
(SAMHSA, 2005; SAMHSA, 2009). An effective long term treatment paradigm for the 
successful treatment of alcohol or opioid dependence is the concomitant use of medications 
that block the effects of drug use in concert with behavior change counseling and 
psychotherapy. Medications which have demonstrated effectiveness in the long term 
treatment of opioid dependence are methadone, buprenorphine (subutex®, suboxone®), and 
naltrexone (Revia®, Depade®) or extended release injectable naltrexone (vivitrol®). 
Pharmacotherapies used in the treatment of alcohol dependence include acamprosate 
(Campral®), disulfiram (antabuse®, antabus®) and naltrexone (Revia®, Depade®) or extended 
release injectable naltrexone (vivitrol®).  
Time in treatment is a reliable indicator for successful treatment of drug dependence. 
Patients remain in treatment for longer periods of time when they perceive that their health 
care environment is supportive and non-stigmatizing, have a good patient-provider 
relationship, and feel that their needs are identified and met. Access to community-based 
substance abuse treatment that includes MAT is fundamental to achieving broad service 
coverage. Given that substance abuse treatment is Human Immunodeficiency Virus (HIV) 
prevention and the frequent co-morbidity of substance abuse and HIV infection, the 
provision of prevention, care and treatment for both need to be addressed in a coordinated 
manner for ideal patient outcomes. There are several models to achieve excellent patient 
outcomes for both HIV infection and the treatment of substance abuse (Proeschold-Bell et al 
2010; Weiss et al, 2011). The highest level of coordinated care model has MAT and HIV 
services fully integrated with both the same medical record and health providers for both 
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services. Alternatively, MAT and HIV services can be separately managed but co-located to 
allow convenient utilization of both MAT and HIV services in another form of “one stop 
shopping”. A third approach is coordinated care and treatment where MAT and HIV 
services are provided at distinct locations, and case managers, peer facilitators, or others 
promote coordination of referrals. This third model can pose significant barriers to 
substance users who are heavily stigmatized and medically disenfranchised and who have 
multiple competing medical, psychological and social needs that limit access to care. MAT 
programs that offer comprehensive services and care options can best contribute to 
improving the health of these individuals thereby reducing HIV infection in the community.  
2. Drug and alcohol use and their linkage to HIV infection  
Exposure to the HIV can result in a patent viral infection. HIV infection can occur via two 
transmission routes: direct injection of the virus through the use of injection equipment 
infected with HIV and through sexual contact with an infected individual. There is a direct 
linkage between these disparate behaviours and drug and alcohol use.  
For people who inject drugs, there is a risk of HIV infection when the injection equipment is 
reused and not sterilized after use or when there is direct sharing of the injection equipment 
with individuals who may be infected with HIV. Drug users who are under the influence of 
drugs may engage in risk behaviours for HIV that they would not while sober. In addition, 
for drug users who develop dependence, withdrawal induced drug cravings may result in 
the exchange of sex for money or drugs or other behaviours that increase risk of HIV 
acquisition. Similarly, alcohol consumption increases sexual risk-taking including high risk 
behaviors (Figure 1). That includes sexual acts without the use of condoms and an increased 
number of sexual partners. Concurrent sexual partnerships are a significant risk factor for 
the transmission of HIV (Epstein & Morris, 2011). Alcohol can also be an important 
contributor in the progression of HIV infection to acquired immune deficiency syndrome 
(AIDS) (Hahn & Samet , 2010). Alcohol consumption is an important consideration in the 
medical management of patients with HIV infection, particularly those co-infected with the 
hepatitis C virus (HCV) (Edlin et al 2001). Studies have also shown that alcohol 
consumption can modify drug metabolism in the liver, and thereby potentially influence the 
effectiveness of HIV antiretroviral therapy. Alcohol-induced cirrhosis can result in changes 
in drug metabolism in the liver through compromised liver function. Research has shown 
that alcohol consumption greater than 50 g/day (4–5 drinks) is a risk factor for disease 
progression for patients with HIV/HCV co-infection. 
All substance abuse, whether the use of opioids, stimulants, or excessive alcohol, can 
negatively influence the course of HIV disease progression when the use results in low 
antiretroviral adherence or facilitates missed medical appointments. Substance abuse has 
been associated with less access to antiretroviral medications, lower medication adherence, 
and increased mortality among HIV infected patients.  
2.1 Alcohol abuse, medication assisted treatment and HIV infection 
Alcohol abuse and dependence are global problems of major medical importance with high 
societal impact (WHO, 2010). In determining the global burden of disease, the World Health 
Organization (WHO) has noted that a leading cause of disability is alcohol and drug use 
disorders. Alcohol consumption is estimated to cause 4% of the total of Disability-Adjusted 
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Life Years and 3.2% of deaths, globally. The WHO estimates that about 2 billion individuals 
worldwide consume alcoholic beverages.  
 
 
Fig. 1. Interactions and linkages between drug and alcohol use and abuse in the course of 
HIV infection and AIDS.  
Alcoholic beverage consumption can be described based on quantity. Abstainers or 
light/occasional drinkers comprise roughly 40% of a general population while moderate 
drinkers comprise about 35% of the general population. Both groups comprise 
approximately 55–75% of a general medical practice. At-risk drinkers, those with hazardous 
drinking patterns or quantities, and alcohol abusers, those with harmful drinking (meeting 
the required clinical criteria) comprise approximately 20% of the population and 20–35% of 
a general medical practice. At-risk drinkers are males who drink more than two drinks a 
day or greater than four drinks per occasion. For females and individuals over the age of 65, 
at-risk drinkers are those who drink greater than one drink per day or greater than three 
drinks per occasion. These individuals consume alcohol at levels that place them at-risk for 
alcohol-related social and/or medical problems (Dufour, 1999). These at-risk individuals are 
best managed through the use of brief interventions that can be provided by primary care 
physicians, health care providers or specialists, upon training. Usually these brief 
interventions are outpatient interventions that include some form of counseling. 
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Approximately 76.3 million individuals have a diagnosable alcohol use disorder. Alcohol 
and drug use disorders are defined clinically as alcohol/drug abuse or dependence (WHO, 
2004). Diagnostic and Statistical Manual of Mental Disorders-4th edition (DSM-IV) 
definitions of abuse and dependence are maladaptive patterns of alcohol or drug use that 
result in clinically significant impairment or distress as well as significant behavior 
modifications. Individuals with alcohol dependence comprise approximately 5% of the 
population and around 5–10% of a general medical practice. Alcohol abusers and alcohol-
dependent individuals exhibit a varying degree of social and/or medical dysfunction. These 
individuals require intensive treatment, including structured counseling and/or 
pharmacotherapy (Fiellin et al., 2000). Severely involved dependent patients have been 
traditionally thought of requiring treatment in a specialty setting. However, studies (Fiellin 
et al., 2000a) have shown that primary care physicians may also have an important role in 
providing treatment to these individuals. 
Pharmacotherapy for alcohol dependence is an important adjunct to behavioral therapies to 
reduce the risk of relapse to drinking after an initial period of abstinence (SAMHSA, 2009). 
Pharmacotherapy for alcohol consumption is also important for patients with co-occurring 
conditions such as patients with HIV and/or HCV infection(s) where alcohol consumption 
can augment disease progression. For these patients alcohol dependence treatment has been 
reported with either acamprosate, naltrexone, vivitrol or disulfiram (Collins et al, 2006). 
Acamprosate and naltrexone have different mechanisms of action and modify different 
behavioral aspects of alcohol dependence. Acamprosate is a long acting compound that 
prolongs periods of abstinence by normalizing glutamateric neurotransmission. 
Glutamateric neurotransmission in the brain is dysregulated during chronic alcohol 
consumption and withdrawal. Naltrexone is a fast acting opioid receptor antagonist that 
reduces heavy drinking through a decrease of the reward effects of ethanol. An evidence-
based risk –benefits assessment can be used to inform health care providers on medication 
choice (Mason, 2003). However, the safety and efficacy of treatment using both medications 
for alcohol dependence has been shown in double blind studies (Kiefer & Wiedemann, 
2004). Disulfiram, another pharmacotherpy option, blocks the oxidation of alcohol at the 
acetaldehyde stage of its metabolism. The increase in the levels of acetaldehyde resulting in 
a series of unpleasant symptoms (e.g., flushing, headache, and vomiting). Although 
disulfiram is widely used, particulalry is the setting of opioid dependence, superior data of 
studies support  the use of naltrexone and acamprosate as pharmacologic treatments of 
alcoholism (Kiefer et al 2005). For resource limited settings, a series of factors acting 
synergistically may be creating the “perfect storm” promoting alcohol availability, alcohol 
consumption, and reducing alcohol control policies, thereby increasing the need for  public 
health efforts (Table 1) to reduce alcohol consumption the beyond the use of medication-
assisted treatment for alcohol abuse and dependence (Caetano & Laranjeira, 2006). 
Use of alcohol may impact the care and course of HIV infection for an individual patient 
(Baum et al, 2010; Hahn & Samet, 2010). Optimal management of HIV infected patients with 
alcohol problems requires recognition of the impact of alcohol on a number of issues: 
patient’s linkage to medical care; adherence to anti-retroviral treatment, impact on co-
morbid conditions (such as HCV infection), liver function, and the stage of HIV disease. Due 
to its many ramifications, the clinical approach to the HIV infected patient with alcohol 
problems takes on a high priority, yet it is similar in many ways to the standard optimal 
approach to any medical patient (Bogart et al., 2000). It requires the effective screening for 
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Table 1. Approaches to Alcohol Use and Abuse in HIV/AIDS 
the prevalent condition of alcohol abuse, assessment of the severity of the alcohol problem, 
and skills to intervene effectively to reduce the harm associated with alcohol use/abuse. 
New strategies to target alcohol use/ abuse in HIV populations need to be implemented in 
the context of existing recommended HIV clinical approaches. Addressing alcohol problems 
in HIV-infected persons has the potential to improve the overall management of HIV 
disease in a substantial proportion of the population 
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2.2 Illicit opioid abuse, medication assisted treatment and HIV infection 
Based on the 2010 World Drug Report (UNODC, 2010) from the United Nations Office on 
Drugs and Crime (UNODC), it is estimated that between 175- 250 million people from 
almost every country, or 5 percent of the global population age 15-64, have used illicit drugs 
at least once in the last 12 months. Cannabis is by far the most widely used drug, followed 
by stimulants, such as amphetamines and ecstasy, then cocaine use and then opioids. While 
most individuals occasionally use or have casually tried illicit drugs, UNODC estimates that 
there are between 18-38 million problem drug users. These individuals consume most of the 
drugs and likely fulfill the criteria for a diagnosis of drug abuse or dependence.  
These medical co-occurring conditions are specifically prevalent in injection drug users 
(IDU). Estimates for IDU’s are available for at least 130 countries with approximately 78% of 
the 13.2 million IDU’s living in developing or transitional countries (Aceijas et al 2004). 
Forty-one countries have reported a high prevalence (>5%) of HIV infection in this high-risk 
population. Globally, IDU’s now account for at least 10% of all new HIV infections which 
are estimated at 5 million per year (IHRDP, 2006). In chronic HIV infection, AIDS has been 
reported as the leading cause of death in IDUs (Chin, 2007). Epidemiological data of HIV 
infection show that generalized HIV epidemics can result from diffusion transmission of 
HIV from high risk groups, such as IDUs. Thus, it is important for countries and regions to 
undertake surveillance studies to identify current alcohol and drug use patterns and 
develop best practices for the treatment of individuals who use and abuse alcohol and illicit 
drugs.  
Drug dependence is a chronic, relapsing neurophysiological disease resulting from the 
prolonged effects of drug(s) on the brain. The neurochemical abnormalities resulting from 
chronic use are the underlying cause of many of the observed physical and behavioral 
aspects of abuse and dependence. The brain abnormalities associated with addiction are 
wide ranging, complex, and long lasting (Chana et al 2006; Goodkin et al 1998; Langford et 
al 2003). They can involve abnormal brain signaling pathways, psychological conditioning 
or stress and social factors that result in cravings leading to a predisposition to relapse even 
months or years after drug(s) use cessation.  Thus, substance abuse/dependence can be 
most effectively addressed in a multifaceted medical-based paradigm that comprises a 
comprehensive program of interventions that are delivered through the course of long term 
treatment. Such comprehensive treatment programs include behavioral, social rehabilitative 
components, as well as biological (pharmacological) components Table 2. Behavioral 
therapy interventions have been extensively researched and are critical components of the 
treatment of all drug addictions.  Social rehabilitative components are also important and 
may prove suited to certain treatment environments. 
In the United States, opioid abuse/dependence can be treated in two differing medical 
paradigms. In the highly regulated and structured environment, methadone is dispensed 
daily at Opioid Treatment Programs (OTPs). These OTPs are increasingly providing “wrap-
around” services to address important patient needs, enhance time in treatment, and 
promote recovery. Alternatively, buprenorphine can be prescribed in a primary care health 
care setting similar to other illnesses to reduce the stigma/discrimination of drug 
dependence. Both medical paradigms need to address the reduced quality of life, physical 
and mental functioning, compared to the general population that is associated with drug 
abuse/dependence (Millson et al. 2006). In addition, multiple comorbidities are associated 
with substance abuse and dependence that also contribute to the lower quality of life  
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Table 2. Elements of the Continuum of Care in the Treatment of Opioid  Abuse/Dependence 
experienced and documented by opioid dependent individuals. Life priorities of opioid 
users have been reported as concern about HIV and treatment of infection with HIV, 
housing, money, and protection from violence (Mizuno et al, 2003).  
Substance abuse is a complex medical disorder composed of multiple physiologic, social 
and behavioral problems often interrelated with psychological illness. Health care providers 
need to screen substance misusing patients for psychological illness (Schuckit, 2006).  
Although it can be difficult to ascertain whether substance abuse, psychological illness, or 
infectious comorbidities should be addressed first, an initial focus on the medical treatment 
of drug abuse is often necessary to create sufficient patient stability from which other 
treatments can begin. Stability is further increased with both mental health services and 
substance abuse treatment, subsequently enhancing the medical outcomes of treatment for 
comorbidities. 
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In the United States, multiple pharmacological treatments, including both agonists and 
antagonists have been developed and approved by the Food and Drug Administration for 
specific drug dependence. Currently, medications and evidence-based treatment paridigms 
utilizing these pharmacotherapies are available for the treatment of nicotine, alcohol, and 
opioid substance use disorders. Although none are available for stimulants, such as cocaine 
and methamphetamine, many potential medications are now being developed for these 
drugs of abuse and are expected to be available over the next few years. An effective 
treatment strategy for drug abuse and dependence is to match a comprehensive treatment 
plan to the individual’s particular substance abuse problems and needs. Desired treatment 
outcomes should:  a) reduce dependence on drugs of abuse, b) reduce morbidity and 
mortality of and associated with drugs of abuse, and c) maximize the patients’ abilities to 
access services and achieve social integration. 
2.2.1 Medication assited treatment utilizing methadone 
In most countries that utilize MAT for the treatment of opioid dependence, methadone is the 
pharmacotherapy of choice. Methadone is usually the least expensive medication and when 
used in evidence-based treatment paridigms is cost effective and can result in abstenence 
from illicit drug use over time and the achievement of recovery (Connock et al 2007;  
Skinner et al 2011). Methadone is a synthetic -opioid receptor agonist with 
pharmacological properties qualitatively similar to morphine and was originally used to 
treat the painful symptoms of withdrawal from heroin and other opioids (Gowing et al 2006; 
Payte & Zweben , 1998). Administered daily as an oral dose for the treatment of opioid 
dependence, an individual therapeutic dosage is determined to maintain an asymptomatic 
state and stabilize a patient, without episodes of opioid overmedication or withdrawal. The 
therapeutic dosage for a patient is a function of many factors including: absorption, 
metabolism, drug-drug interactions, physiology, diet and the use of alternative medications.  
Minimum retention time in treatment varies for residential and outpatient methadone 
treatment programs. The National Institutes of Health consensus panel on opioid-addiction 
treatment (NIH, 1997) concluded that individuals treated for fewer than three months with 
methadone do not show substantial medical gain. As time in treatment progresses, study 
outcomes have reported partial reductions of illicit opioid use progressing to abstinence. 
Relapse to opioid use is common when methadone is discontinued without further support 
or behavioral treatment. In the United States, OTPs or methadone maintenance treatment 
programs, MMTP, under the certification of the Substance Abuse and Mental Health 
Services Administration (SAMHSA), dispense methadone and can provide a comprehensive 
therapeutic milieu comprised of primary medical care, psychosocial counseling, vocational 
rehabilitation, HIV testing and counseling, hepatitis C education and testing and other vital 
medical and social services. Methadone treatment is effective as both primary and 
secondary HIV prevention (Kerr et al 2004) and cost-effective to society (Barnett et al 2001; 
Doran et al 2003). In addition to improving health outcomes, methadone treatment also 
substantially improves the quality of life of patients over the course of methadone treatment 
(Giacomuzzi et al 2005). 
Barriers to retention in methadone treatment include the severity of drug, medical and 
social problems at initiation of treatment, as well as patient readiness for treatment and 
motivation. Integrating multiple components of the drug treatment program is fundamental 
to successful treatment outcomes. Treatment programs that offer a broader array of “wrap-
around” services and a greater frequency of services have reported improved retention in 
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treatment and treatment outcomes (Fiellin et al 2003). Programs responsive to the severity of 
drug abuse during initial stages of drug treatment have been shown to produce positive 
treatment outcomes based on greater retention time in treatment and patient satisfaction 
with treatment services. Maximum retention time in methadone treatment is associated with 
comprehensive treatment, provision of frequent health service, as well as appropriate 
methadone dosing (Litwin et al 2001).  
2.2.2 Medication assited treatment utilizing buprenorphine 
In the United States and globally, primary care physicians can expand the accessibility of 
substance abuse treatment while mitigating the stigma associated with drug use and 
treatment through an outpatient treatment setting in primary care and the use of 
buprenorphine. However, in the United States, buprenorphine-only OTPs have been 
recently developed where buprenorphine is provided to opioid dependent patents under 
the highly regulated rules and regulations that apply to methadone. Buprenorphine, a 
partial mu-receptor opiate agonist (Ling & Smith 2002), differs significantly from full 
agonists. Most significantly, buprenorphine has a plateau of its agonist properties at higher 
doses. This results in an improved safety profile compared with a full agonist. Specifically, 
buprenorphine has a favorable ‘ceiling effect’ on respiratory depression precluding 
overdose potential (Walsh et al 1994).  However, the abuse of other substances that may 
enhance respiratory depression (e.g., benzodiazepines) remains a contraindication with 
buprenorphine as with methadone. Improved safety and thrice weekly flexible dosing 
promotes patient acceptance. In addition, buprenorphine has two features that decrease 
street diversion. Buprenorphine can precipitate opiate withdrawal when buprenorphine is 
taken by an opiate dependent patient (Schuh et al. 1996) and buprenorphine can be 
marketed both alone (Subutex®) and in combination with naloxone (Suboxone®). In the 
latter formulation, if it is crushed and injected, acute opiate withdrawal symptoms will 
ocuur which are a potent disincentive for prescription opioid abuse (Yokell et al. 2011).  
2.2.3 Medication assited treatment utilizing naltrexone 
Naltrexone is a non-narcotic long-acting, opioid antagonist that blocks the euphoric effects of 
opioids binding the mu opioid receptor. Unlike methadone, there is no negative reinforcement 
(opioid withdrawal) upon discontinuation. Due to naltrexone’s opioid antagonism, patients 
must abstain from opioids for a minimum of seven days prior to starting treatment to avoid 
the precipitation of opioid withdrawal. The effectiveness of naltrexone treatment depends 
upon patient motivation and social support system (Greenstein et al 1983). Thus, in cultures 
where there is strong family or social support for the patient in care, oral naltrexone has been 
shown to be effective in the prevention of relapse to heroin use (Krupitsky et al 2010). Because 
of a lack of positive reinforcing effects with naltrexone and low motivation on the part of many 
patients, as well as, poor clinician acceptability, it is not widely prescribed for the treatment of 
opioid dependence in the United States.  
Vivitrol is an injectable extended-release formulation of naltrexone that has recently been 
approved for the treatment of opioid abuse and dependence. Vivitrol addresses the concern of 
medication adherence as a monthly injectable formulation and has been shown to be more 
effective than oral naltrexone (Krupitskya & Blokhina, 2010). This was also shown in a recent 
Phase 3 clinical trial that confirmed vivitrol’s safety and efficacy in the prevention of relapse to 
heroin use in a cohort of injection drug users. A higher retention in care and higher rates of 
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opioid-free urine screens were observed along with a significant reduction in opioid craving 
compared to placebo. Currently, studies are underway to determine the most efficacious 
service model(s) for the use of vivitrol in the treatment of relapse prevention to heroin use.  
3. Medication assisted treatment: Stages of treatment and recovery 
The stages or phase of MAT are shown in Table 3. The patient travels through these three 
stages of treatment, sometimes linearly and sometimes with oscillations between phases. 
The ultimate goal upon entering MAT is a good clinical outcome which includes the  
 
 
Table 3. Stages or Phases of MAT 
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recovery from opioid abuse and dependence and social reintegration back into society. The 
individual in recovery is a functioning member of the community and contributes to the 
social fiber and health of the community. Thus, a foundation of MAT is the obtainment of 
Recovery from opioid abuse and dependence (Davidson & White , 2007).  
The recovery process is the individual way in which a person actively manages their 
substance use disorder with efforts to reclaim full functional and meaningful lives in the 
community. Recovery is personal process of growth and change which embraces hope, 
autonomy and the elements that result in establishing a satisfying and productive life. MAT 
is a recovery oriented system of care when integrated with other medical, social and 
rehabilitative services in support of the individual’s and family’s long term efforts to reclaim 
full and meaningful lives in the community. Important in recovery is the provision of 
comprehensive services in the context of MAT but also a supportive, enabling environment 
that fosters individual responsibility over one’s health and empowerment to change to a 
healthy lifestyle (Sowers, 2005). 
MAT, as a recovery orientated system of care, has four phases as shown in Table 4, along 
with a set of recovery oriented goals, strategies, and services (White & Mojer-Torres, 2010). 
An important consideration in phase four, long term sustained recovery, is the personal 
decision to continue with medical maintenance of pharmacotherapy or to taper the 
medication. In either case, the home or living environment is critical to the prevention of 
relapse to opioid use. To prevent relapse of opioid use the individual in recovery needs a 
drug free environment. While significant gains have been made through national prevention 
programs such as “Drug Free Communities”, it remains a Herculean task to keep a 
community entirely free of illicit drug use. Thus, for long term recovery the home or living 
environment is where recovery is nucleated (Ashcraft et al, 2008). Local peer recovery 
programs as well as recovery oriented systems of care that link to or provide individualized, 
quality long term supportive care are critical (Jason & Ferrari, 2010). These settings provide 
a network of people to support abstinence as well as a low risk environment to support 
recovery. Receiving abstinence support, guidance and information from a recovery home, 
that is committed to long term sobriety, reduces the risk of relapse to illicit opioid use. These 
homes need to be considered as a fundamental component in the development and 
maintenance of the public health of communities. 
4. Service models for medication assisted treatment 
Health service programs deliver MAT in a regulatory environment where both the federal 
government and state/local government provide a regulatory framework for the access to 
and delivery of medications that are controlled by international convention (Kresina et al, 
2009). In the United States, state and local regulation can enhance the federal regulations but 
they can not negate the federal regulations. The MAT federal regulations can be found in the 
Code of Federal Regulations (CFR, 2002) and establish procedures to determine if a health 
practitioner is qualified to dispense methadone in the treatment of opioid abuse and 
dependence in opioid treatment programs, as well as, the quantity of methadone that can be 
provided for unsupervised use by patients. Thus, the federal regulations address the balance 
needed in the use of controlled medications for treatment versus the restrictions to limit 
diversion of the controlled medication (Yokell et al 2011).  
The MAT federal regulations do not regulate the health service models that can be use to 
maximize access to MAT as well as time in treatment. These are two important  
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Table 4. Phases and Goals of MAT Recovery Oriented Systems of Care 
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characteristics to maximize as one designs model MAT programs to ensure good clinical 
and public health outcomes. Barrier free access to MAT is important for obtaining maximal 
public health impact and reaching all opioid abusing individuals seeking treatment. 
Research studies have shown that the more time in MAT the better the treatment outcome. 
Thus, MAT programs providing comprehensive services as part of the continuum of care 
(see Table 2) in an enabling environment result in quality and effective substance abuse 
treatment services that promote individual well-being and improved community health.  
4.1 Integrated models of medication assisted treatment 
Health service models for MAT that provide comprehensive services interface substance 
abuse treatment services with primary medical care and social/rehabilitation services. That 
interface can be comprehensive through the integration of substance abuse treatment 
services, primary medical care, infectious disease prevention, care and treatment and 
social/rehabilitation services. An integrated care and treatment model, where MAT services 
are provided within primary care using a single medical record, minimizes the sigma and 
discrimination associated with drug treatment services while improving overall health 
outcomes in a cost-effective manner (Collins et al 2010).  
For OTPs dispensing methadone, primary medical care and social/rehabilitation services 
are integrated on-site in the structured environment where methadone is dispensed 
(Freidman et al 1999; Kresina et al 2008). Based on patient needs, various types of health 
services can be integrated into OTP MAT services including primary care, mental health, 
and infectious diseases. Specific limiting factors for the integration of services have been 
shown to be the organizational structure of the OTP and cost. 
Buprenorphine, a less regulated opioid agonist medication, is approved in the United States 
for office based opioid treatment. An office based setting provides enhanced treatment 
access to MAT using buprenorphine in a less stigmatized environment  enabling integrated 
medical care of infectious diseases and co-morbid conditions (Gunderson & Fiellin , 2008). 
Multiple models have been piloted for the integration of MAT using buprenorphine within 
HIV primary care (Sullivan et al 2006). These include an on-site combination of addiction 
treatment/HIV specialist treatment; a HIV primary care physician prescribing 
buprenorphine; a non-physician health care provider integrating medical care and substance 
abuse treatment services using buprenorphine; and a community outreach model where 
buprenorphine is provided along with medical services in a mobile van. These pilot projects 
have uncovered barriers to integrating MAT using buprenorphine within HIV primary care 
that are both financial and regulatory. Regulatory challenges include licensing and training 
restrictions imposed by the Drug Addiction Treatment Act of 2000 and confidentiality 
regulations for alcohol and drug treatment records (Schackman et al 2006). A recent study 
has shown that in a primary care setting that used buprenorphine, prescription opioid 
dependent patients showed better clinical outcomes compared to patients who were 
dependent on heroin (Moore et al, 2007).  
Naltrexone is a non-narcotic and therefore non-controlled medication for the treatment of 
opioid abuse as well as alcohol abuse. Naltrexone integrated with mental health services, 
particularly psychosocial treatment has been shown to be an effective maintenance 
treatment for reducing heroin use after detoxification (Minozzi et al. 2006). In addition, 
using clonidine and naltrexone together has been shown to be successfully integrated into a 
primary care setting (O’Connor et al. 1997). In this study retention in care and successful 
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detoxification from opioid abuse was observed with MAT using either naltrexone or 
buprenorphine. In other care settings, treatment of alcohol use disorders using naltrexone 
has been successfully integrated into the treatment of patients who have tuberculosis 
(Greenfield et al. 2010). Current efforts are determining the optimum conditions to integrate 
vivitrol (extended release naltrexone) into HIV primary care programs. Additionally, how to 
integrate vivitrol into an OTP setting and in primary medical care as a relapse prevention 
intervention for patients following their completion of maintenance treatment with either 
methadone or buprenorphine, is currently moving forward.  
4.2 Coordinated care models of medication assisted treament 
Health service models for MAT that provide comprehensive services can connect 
substance abuse treatment services with primary medical care and social/rehabilitation 
services in a non-integrated but coordinated fashion. Here, MAT services coordinate with 
primary medical care and social/rehabilitation services to promote good patient outcomes 
and enhance community health. MAT, health services and social/rehabilitation services 
can be separately managed with a different network of health care providers but co-
located to allow convenient utilization of primary care, MAT and other services. An 
additional coordinated approach provides primary care, MAT and other services at 
distinct locations through a differing network of health care providers. As shown in a 
recent study where twice as many patients retained in MAT when the MAT services were 
provided at single location compared to referral of MAT to a distant location (Lucas et al 
2010), providing needed health services at distinct locations is less than optimal. 
However, coordinated programs can be effective when case managers, peer facilitators, 
care navigators or others promote or support service utilization at the various locations. 
For example, a referral system intervention was modeled with linkages to treatment 
services for substance use, mental health and social services for HIV+ patients receiving 
HIV primary care (Zaller et al. 2007). Patients receiving the intervention were referred to 
MAT either at an OTP or in an office based setting that prescribed buprenorphine. An 
alternative model provided highly stable OTP patients with 28 days of methadone doses 
and required monthly check-ins. Successful patients were noted to have increased family 
and social activities and failed patients were provided stepped treatment intensification 
(King et al. 2006). Community –wide health service delivery programs also provide an 
alternative to integration through enhanced access to networked drug treatment and co-
morbidity health services (Neufeld et al 2010).  
Unique to buprenorphine is the model that a substance abuse treatment specialist provides the 
initial treatment (induction) with buprenorphine until the patient is stabilized. Then the 
patient is transferred/referred to a primary care physician who can then provide maintenance 
buprenorphine treatment and medical primary care. This so called ‘wheel and spoke model’ 
allows for substance abuse treatment specialists to manage the more difficult portion of 
buprenorphine treatment (early treatment –or induction phase) while the primary care 
medical program manages the long term maintenance phase of buprenorphine treatment (BBI, 
2008). This model is important in the United States since the Drug Addiction Treatment Act of 
2000 limits the number of patients a qualified buprenorphine treatment provider can manage 
in their practice (DATA, 2000). This model has been adapted to HIV+ patients where the 
buprenorphine induction is performed by the substance abuse treatment specialist and then 
the patient is transferred/ referred to the HIV primary care physician (Basu et al. 2006).  
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Coordinated MAT for patients seeking relapse prevention interventions after detoxification 
from opioid use can be provided by naltrexone or the recently approved vivitrol. As noted 
earlier, naltrexone it is not widely prescribed for the treatment of opioid dependence in the 
United States, but is provided as an office based treatment for opioid dependence after 
detoxification. In addition, studies have shown that the extended release formulations are 
effective in reducing opioid use and retaining patients in care after detoxification (Comer et 
al 2006; Kunoe et al. 2010). Fishman et al 2010 has shown good clinical outcomes (retention 
in care and reduced opioid use) for adolescents receiving vivitrol over a four month period. 
This study is important because of the limted use of controlled pharmacotherapies in 
adolescent populations as part of national regulatory frameworks.      
5. Preventing HIV infection by integration of medication assisted treatment 
into HIV prevention services 
Important HIV prevention interventions for people who inject drugs are the provision of 
clean needles and syringe through syringe service programs and  associated HIV testing and 
counseling programs. These HIV prevention interventions, when integrated into MAT 
programs, maximize the enrollment in treatment programs for opioid and alcohol abuse, 
and thereby maximize HIV prevention efforts (Kidorf et al 2009; Lloyd et all 2005). 
Maximizing HIV prevention efforts targeting peple who use drugs and those dependent on 
opioids and alcohol are critcial to prevent HIV infection in these most-at –risk populations. 
Integrating drug abuse treatment and early HIV prevention interventions, particulaly HIV 
testing and counseling, are important as components of the newly emerging   Seek,Test, 
Treat and Retain“ strategy ( Crawford & Vlahov, 2010; Taege, 2011). This is an engagement 
and retention strategy that outreach workers can employ with injection drug users to reduce 
their risk for HIV infection. By utilizing outreach workers to seek out most-at-risk people 
who inject drugs, establish their HIV status through HIV testing, followed by sexual risk 
reduction councelling, HIV risk behaviors can be addressed with subsequent emphasis on 
treatment for their substance use disorder.  
Unfortuately, there is not signifcant integration of HIV testing and counseling in OTPs. In the 
US, while approaximely 90% of opioid treatment programs provide some form of federally 
mandated HIV/AIDS education,  only 74% of opiod treatment progams offered HIV testing 
(Kresina et al 2005). These services appear underutilized in that approximately one-in-three 
persons receiveving subtance abuse treatment also received HIV testing and counselling 
(Pollack & D’Aunno, 2010). Globally, although subtantial efforts are being made to increase the 
availability of HIV testing, most-at-risk populations remain underserved with regard to HIV 
prevention service utilization. It is estimated that only 10% of persons at-risk for HIV infection 
receive HIV testing. Thus, strategies such as opt-out testing, home-based testing, dor-to-door 
testing as well as providing dedicated HIV testings counselors at point-of-service locations are 
being utilized to enhance the uptake of HIV testing for people who use alcohol and  inject 
drugs. Studies have shown that most-at-risk populations prefer point-of-service HIV testing, 
however, this intervention requires additional measures to support HIV positive individuals 
entering into HIV care and treatment (Keller et al 2011). 
6. Preventing HIV transmission by integration of medication assisted 
treatment into HIV care and treatment 
A significant factor in not reducing the global HIV epidemic is the lack of entrance into HIV 
care and treatment by most-at-risk populations. These populations, which include illicit 
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drug users and alcohol abusers, encounter numerous barriers in accessing HIV care and 
treatment. In addition, once in treatment these individuals often suffer stigma and 
discrimination as they receive their needed medical care. The result is an increase in the 
prevalence of medical and psychiatric co-morbidities as well as social issues and high risk 
behaviors, in addition to worse clinical outcomes with a higher mortality rate compared to 
the non-drug and non-alcohol using populations infected with HIV (Altice et al 2010).   
The increased mortally rate noted in people who inject drugs is related to their late 
presentation for HIV care. Patients who present late for care and treatment of HIV/AIDS are 
at a higher risk of significant clinical complications and are thus more difficult to clinically 
manage. Late presentation for treatment of HIV/AIDS is a common scenario leading to 
death (Moreno et al 2010). A recent study has documented a highly lethal neurological 
syndrome found in HIV-infected drug abusers (Newsome et al 2011). Although rare, the 
newly described syndrome is highly lethal with a mean survival time of 21 days after 
diagnosis. The authors suggest that access and initiation of antiretroviral therapy may 
provide a better outcome for these patients. In addition, substance abuse treatment, 
particularly MAT, which has been shown to enhance the health status, reduce mortality and 
quality of life of injection drug users, would be an important adjunct to anti-retroviral 
treatment for these patients. Thus, as noted earlier integrating both MAT with anti-retroviral 
treatment in a HIV primary care setting is a paradigm to optimize health outcomes and the 
health status of HIV-infected injection drug users. 
How MAT is integrated in HIV primary care programs depends on the country’s regulatory 
framework. In the United States, all medications accept methadone, can be prescribes to 
patients in a HIV primary care or outpatient HIV clinical care setting. The federal 
regulations in the United States require methadone to be dispenses in OTPs. However, in 
this setting studies have shown that HIV care and anti-retroviral treatment can be effectively 
prescribed either as directly observed therapy or as routine care. Other countries, such as 
Australia, have less stringent federal regulations for prescribing controlled medications and 
all medications comprising MAT can be provided in a primary care setting. In either case, 
the important aspect of providing integrated MAT and HIV primary care is the single 
location/clinic. In that case, the patient can receive all the needed services to support their 
recovery from drug/alcohol dependence as well as care and treatment for HIV infection. 
7. Essential health interventions for the prevention of HIV infection in people 
who inject opioids  
The WHO, UNODC and UNAIDS has approved and advocates for a package of essential 
interventions for the prevention, treatment and care of HIV for people who inject drugs 
(WHO, 2009a). These evidence based intervention, shown in Table 6, need three important 
characteristics in their implementation to maximize effectiveness. These interventions need 
to be part of a public health policy that is human rights based, gender responsive, and 
community owned.  
As noted earlier, no single intervention alone will prevent or reverse to growing national 
HIV epidemics due to injection drug use and abuse. However, the greatest impact will be 
obtained when the interventions are provided through an integrated services platform in a 
comprehensive fashion. And in order to reach all of those seeking HIV prevention, care and 
treatment services, health service platforms need to provide an enabling environment that 
establishes confidentiality. In addition, they also need to develop patient –provider trusting 
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relationships. Both community outreach and peer –to-peer services can promote full service 
utilization. The national Ministries of Health need to embrace and support these health 
services and interventions through a supportive legal and policy framework validating their 
place in the public health area and in society as they improve community health.   
 
 
Table 5. Listing of Internationally Accepted Essential Interventions for HIV 
8. Conclusion 
Substance abuse treatment is HIV prevention. The use of medication assisted treatment as a 
component of a comprehensive treatment plan for those individuals who abuse opioids 
and/or alcohol is an effective, evidence-based treatment paradigm that results in good 
medical outcomes including a reduction in HIV transmission as well as a reduction of 
incident infections in opioid and alcohol abusing populations.      
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